Novel Application of Aptamer Proteomic Analysis in Cystic Fibrosis Bronchoalveolar Lavage Fluid

Purpose: Biomarkers are needed in cystic fibrosis (CF) to understand disease progression, assess response to therapy, and enrich enrollment for clinical trials. Aptamer‐based proteomics have proven useful in blood samples. The aim is to evaluate proteins in bronchoalveolar lavage fluid (BALF) in CF children compared to controls and identify endotypes during CF exacerbations.

[1]  J. Harris,et al.  Pulmonary Aptamer Signatures in Children's Interstitial and Diffuse Lung Diseases. , 2019, American journal of respiratory and critical care medicine.

[2]  T. Welte,et al.  Morphological and molecular motifs of fibrosing pulmonary injury patterns , 2019, The journal of pathology. Clinical research.

[3]  R. Deterding,et al.  Proteomic profiling identifies novel circulating markers associated with bronchiectasis in cystic fibrosis , 2017, Proteomics. Clinical applications.

[4]  David L. Gibbs,et al.  Combining Dependent P-values with an Empirical Adaptation of Brown’s Method , 2015, bioRxiv.

[5]  Mark R Segal,et al.  Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease. , 2016, JAMA.

[6]  Henning Hermjakob,et al.  The Reactome pathway Knowledgebase , 2015, Nucleic acids research.

[7]  D. Nichols,et al.  Inflammation and its genesis in cystic fibrosis , 2015, Pediatric pulmonology.

[8]  S. Heltshe,et al.  Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation. , 2015, Annals of the American Thoracic Society.

[9]  K. Ling,et al.  Matrix metalloproteinase activation by free neutrophil elastase contributes to bronchiectasis progression in early cystic fibrosis , 2015, European Respiratory Journal.

[10]  O. Sommerburg,et al.  Airway mucus obstruction triggers macrophage activation and matrix metalloproteinase 12-dependent emphysema. , 2014, American journal of respiratory cell and molecular biology.

[11]  Waldemar Swiercz,et al.  Automated CT scan scores of bronchiectasis and air trapping in cystic fibrosis. , 2014, Chest.

[12]  R. Deterding,et al.  Bronchoalveolar lavage fluid cytokine profiles in neuroendocrine cell hyperplasia of infancy and follicular bronchiolitis , 2013, Orphanet Journal of Rare Diseases.

[13]  D. Sin,et al.  Systematic review of blood biomarkers in cystic fibrosis pulmonary exacerbations. , 2013, Chest.

[14]  M. Rosenfeld,et al.  Early intervention studies in infants and preschool children with cystic fibrosis: are we ready? , 2013, European Respiratory Journal.

[15]  S. Sagel,et al.  Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. , 2012, American journal of respiratory and critical care medicine.

[16]  L. Stein,et al.  Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome , 2012, Cancers.

[17]  J. Elborn,et al.  Protein biomarkers in cystic fibrosis research: where next? , 2010, Genome Medicine.

[18]  Tracy R. Keeney,et al.  Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, Nature Precedings.

[19]  W. T. Harris,et al.  Association of lower airway inflammation with physiologic findings in young children with cystic fibrosis , 2009, Pediatric pulmonology.

[20]  S. Gharib,et al.  Mapping the lung proteome in cystic fibrosis. , 2009, Journal of proteome research.

[21]  D. Porteous,et al.  Biomarkers for cystic fibrosis lung disease: application of SELDI-TOF mass spectrometry to BAL fluid. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[22]  Frederick P Roth,et al.  Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[23]  F. Accurso,et al.  Patterns of neutrophil serine protease‐dependent cleavage of surfactant protein D in inflammatory lung disease , 2008, Journal of leukocyte biology.

[24]  B. Mecham,et al.  Individual Matrix Metalloproteinases Control Distinct Transcriptional Responses in Airway Epithelial Cells Infected with Pseudomonas aeruginosa , 2007, Infection and Immunity.

[25]  J. Carlin,et al.  Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patients. , 2007, Clinical chemistry.

[26]  A. Edelman,et al.  Cystic fibrosis enters the proteomics scene: New answers to old questions , 2006, Proteomics.

[27]  T. Kirikae,et al.  Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. , 2005, Chest.

[28]  S. Sagel,et al.  Induced sputum matrix metalloproteinase‐9 correlates with lung function and airway inflammation in children with cystic fibrosis , 2005, Pediatric pulmonology.

[29]  J. Uddin,et al.  Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway , 2004, Nature Immunology.

[30]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[31]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[32]  J. Wright,et al.  Surfactant protein D stimulates phagocytosis of Pseudomonas aeruginosa by alveolar macrophages. , 1999, American journal of respiratory cell and molecular biology.

[33]  J. Emerson,et al.  Microbiology of sputum from patients at cystic fibrosis centers in the United States. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  F. Ratjen,et al.  Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis , 1997, Pediatric pulmonology.

[35]  M. Konstan,et al.  Inflammatory cytokines in cystic fibrosis lungs. , 1995, American journal of respiratory and critical care medicine.

[36]  D. Riches,et al.  Early pulmonary inflammation in infants with cystic fibrosis. , 1995, American journal of respiratory and critical care medicine.

[37]  David A. Freedman,et al.  A Nonstochastic Interpretation of Reported Significance Levels , 1983 .

[38]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.